Prognosis algorithms for acute decompensation of cirrhosis and ACLF

Author:

Valainathan Shantha R.123ORCID,Xie Qing4ORCID,Arroyo Vicente5ORCID,Rautou Pierre‐Emmanuel12ORCID

Affiliation:

1. Université Paris‐Cité, Inserm, Centre de recherche sur l'inflammation, UMR 1149 Paris France

2. AP‐HP, Hôpital Beaujon, Service d'Hépatologie, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE‐LIVER Clichy France

3. Service de Réanimation polyvalente Centre hospitalier Victor Dupouy Argenteuil France

4. Department of Infectious Diseases Ruijin Hospital Shanghai Jiaotong University School of Medicine Shanghai China

5. European Foundation for Study of Chronic Liver Failure, EF‐Clif Barcelona Spain

Abstract

AbstractAccurate prediction of survival in patients with cirrhosis is crucial, as patients who are unlikely to survive in the short‐term need to be oriented to liver transplantation and to novel therapeutic approaches. Patients with acute decompensation of cirrhosis without or with organ dysfunction/failure, the so‐called acute‐on‐chronic liver failure (ACLF), have a particularly high short‐term mortality. Recognizing the specificity of this clinical situation, dedicated classifications and scores have been developed over the last 15 years, including variables (e.g. organ failures and systemic inflammation) not part of the formerly available cirrhosis severity scores, namely Child‐Pugh score or MELD. For patients with acute decompensation of cirrhosis, it led to the development of a dedicated score, the Clif‐C‐AD score, independently validated. For more severe patients, three different scoring systems have been proposed, by European, Asian and North American societies namely Clif‐C‐ACLF, AARC score and NASCELD‐ACLF respectively. These scores have been validated, and are widely used across the world. The differences and similarities between these scores, as well as their validation and limitations are discussed here. Even if these scores and classifications have been a step forward in favouring homogeneity between studies, and in helping making decisions for individual patients, their predictive value for mortality can still be improved as their area under the ROC curve does not exceed .8. Novel scores including biomarkers reflecting the pathophysiology of acute decompensation of cirrhosis might help reach that goal.

Funder

Horizon 2020 Framework Programme

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3